Self-aggregating long-acting injectable microcrystals

Authors:

Abstract
Injectable drug depots have transformed our capacity to enhance medication adherence through dose simplification. Central to patient adoption of injectables is the acceptability of needle injections, with needle gauge as a key factor informing patient discomfort. Maximizing drug loading in injectables supports longer drug release while reducing injection volume and discomfort. Here, to address these requirements, we developed self-aggregating long-acting injectable microcrystals (SLIM), an injectable formulation containing drug microcrystals that self-aggregate in the subcutaneous space to form a monolithic implant with a low ratio of polymer excipient to drug (0.0625:1 w/w). By minimizing polymer content, SLIM supports injection through low-profile needles (−1). We demonstrate in vitro and in vivo that self-aggregation is driven by solvent exchange at the injection site and that slower-exchanging solvents result in increased microcrystal compaction and reduced implant porosity. We further show that self-aggregation enhances long-term drug release in rodents. We anticipate that SLIM could enable low-cost interventions for contraceptives.
Funding Information
  • Bill and Melinda Gates Foundation (INV-064313)
  • The Karl van Tassel (1925) Career Development Professorship from the Department of Mechanical Engineering, Massachusetts Institute of Technology
  • Schmidt Science Fellows postdoctoral fellowship from Schmidt Futures and the Rhodes Trust
  • Takeda Fellowship from Takeda Pharmaceutical Company Warren M. Rohsenow Fellowship from MIT Kwanjeong Educational Foundation Fellowship
  • The Heyning-Roelli Foundation Swiss-American Foundation Swiss-European Mobility Programme Worldwide Projects
  • Natural Sciences and Engineering Research Council of Canada (NSERC) postdoctoral fellowship.

This publication has 37 references indexed in Scilit: